NZ613078B2 - Ectoparasitic Treatment Method and Composition - Google Patents
Ectoparasitic Treatment Method and Composition Download PDFInfo
- Publication number
- NZ613078B2 NZ613078B2 NZ613078A NZ61307813A NZ613078B2 NZ 613078 B2 NZ613078 B2 NZ 613078B2 NZ 613078 A NZ613078 A NZ 613078A NZ 61307813 A NZ61307813 A NZ 61307813A NZ 613078 B2 NZ613078 B2 NZ 613078B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- neonicotinoid
- sheep
- thiacloprid
- animal
- lice
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 38
- 239000005940 Thiacloprid Substances 0.000 claims abstract description 30
- HOKKPVIRMVDYPB-UVTDQMKNSA-N Thiacloprid Chemical compound C1=NC(Cl)=CC=C1CN1C(=N/C#N)/SCC1 HOKKPVIRMVDYPB-UVTDQMKNSA-N 0.000 claims abstract description 30
- 241000283898 Ovis Species 0.000 claims description 59
- 241001113967 Bovicola ovis Species 0.000 claims description 17
- 238000002347 injection Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 14
- 241001674048 Phthiraptera Species 0.000 abstract description 59
- 239000000126 substance Substances 0.000 description 28
- 210000003491 Skin Anatomy 0.000 description 24
- 241000283690 Bos taurus Species 0.000 description 16
- 244000045947 parasites Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 8
- PNVJTZOFSHSLTO-UHFFFAOYSA-N Baytex Chemical compound COP(=S)(OC)OC1=CC=C(SC)C(C)=C1 PNVJTZOFSHSLTO-UHFFFAOYSA-N 0.000 description 7
- 241000322476 Bovicola bovis Species 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 244000078703 ectoparasites Species 0.000 description 7
- 230000000749 insecticidal Effects 0.000 description 7
- 239000002917 insecticide Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 206010061217 Infestation Diseases 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 239000004540 pour-on Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 210000002268 Wool Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 210000004027 cells Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000001603 reducing Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000005660 Abamectin Substances 0.000 description 3
- 229950008167 Abamectin Drugs 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- BXNANOICGRISHX-UHFFFAOYSA-N Coumaphos Chemical compound CC1=C(Cl)C(=O)OC2=CC(OP(=S)(OCC)OCC)=CC=C21 BXNANOICGRISHX-UHFFFAOYSA-N 0.000 description 3
- QLFZZSKTJWDQOS-YDBLARSUSA-N Doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 229960003997 doramectin Drugs 0.000 description 3
- 244000144992 flock Species 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 230000002035 prolonged Effects 0.000 description 3
- 230000012865 response to insecticide Effects 0.000 description 3
- 239000004544 spot-on Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AZSNMRSAGSSBNP-XPNPUAGNSA-N 22,23-dihydroavermectin B1a Chemical compound C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 AZSNMRSAGSSBNP-XPNPUAGNSA-N 0.000 description 2
- 241000322475 Bovicola Species 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 210000002615 Epidermis Anatomy 0.000 description 2
- WPNHOHPRXXCPRA-TVXIRPTOSA-N Eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 description 2
- 210000003780 Hair Follicle Anatomy 0.000 description 2
- 229960002418 Ivermectin Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YZBLFMPOMVTDJY-LSGXYNIPSA-N Moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)/C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-LSGXYNIPSA-N 0.000 description 2
- 229960004816 Moxidectin Drugs 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 229940068968 Polysorbate 80 Drugs 0.000 description 2
- 229920003080 Povidone K 25 Polymers 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 229920004482 WACKER® Polymers 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960002346 eprinomectin Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 230000001665 lethal Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000000590 parasiticidal Effects 0.000 description 2
- 239000002297 parasiticide Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- RFEJUZJILGIRHQ-XRIOVQLTSA-N 2,3-dihydroxybutanedioic acid;3-[(2S)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)C(O)C(O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 RFEJUZJILGIRHQ-XRIOVQLTSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- 240000000254 Agrostemma githago Species 0.000 description 1
- 235000009899 Agrostemma githago Nutrition 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 241001283755 Bovicola caprae Species 0.000 description 1
- 241000257161 Calliphoridae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEDTXTNSFWUXGQ-UHFFFAOYSA-N Carbophenothion Chemical compound CCOP(=S)(OCC)SCSC1=CC=C(Cl)C=C1 VEDTXTNSFWUXGQ-UHFFFAOYSA-N 0.000 description 1
- 241000268912 Damalinia Species 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N Diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 239000005906 Imidacloprid Substances 0.000 description 1
- YWTYJOPNNQFBPC-UHFFFAOYSA-N Imidacloprid Chemical compound [O-][N+](=O)\N=C1/NCCN1CC1=CC=C(Cl)N=C1 YWTYJOPNNQFBPC-UHFFFAOYSA-N 0.000 description 1
- 210000002510 Keratinocytes Anatomy 0.000 description 1
- 208000009874 Lice Infestations Diseases 0.000 description 1
- 241001113970 Linognathus Species 0.000 description 1
- 241000670113 Linognathus africanus Species 0.000 description 1
- 241000670112 Linognathus ovillus Species 0.000 description 1
- 229940029985 MINERAL SUPPLEMENTS Drugs 0.000 description 1
- XYFMGGWVGACNEC-UHFFFAOYSA-N N-carbamoyl-N-phenylbenzamide Chemical compound C=1C=CC=CC=1N(C(=O)N)C(=O)C1=CC=CC=C1 XYFMGGWVGACNEC-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 210000001732 Sebaceous Glands Anatomy 0.000 description 1
- 210000002374 Sebum Anatomy 0.000 description 1
- 210000004243 Sweat Anatomy 0.000 description 1
- 210000000106 Sweat Glands Anatomy 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- FSAVDKDHPDSCTO-WQLSENKSSA-N [(Z)-2-chloro-1-(2,4-dichlorophenyl)ethenyl] diethyl phosphate Chemical compound CCOP(=O)(OCC)O\C(=C/Cl)C1=CC=C(Cl)C=C1Cl FSAVDKDHPDSCTO-WQLSENKSSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000000507 anthelmentic Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- -1 boluses Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001055 chewing Effects 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- WGWJBWHBOKETRC-UHFFFAOYSA-N diethoxy-(3-methyl-4-methylsulfanylphenoxy)-sulfanylidene-$l^{5}-phosphane Chemical group CCOP(=S)(OCC)OC1=CC=C(SC)C(C)=C1 WGWJBWHBOKETRC-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000001793 endectocide Effects 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940056881 imidacloprid Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002728 pyrethroid Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000002393 scratching Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Abstract
613078 Disclosed is a method of treating a non-human animal infested with biting lice characterised by the step of administering internally to the animal a pharmaceutically effective amount of neonicotinoid such that the neonicotinoid is present systemically within the animal. Example of a neonicotinoid is thiacloprid. Also disclosed is a dosage regime for a non-human animal. otinoid is thiacloprid. Also disclosed is a dosage regime for a non-human animal.
Description
James & Wells ref: 133719/3
ECTOPARASITIC TREATMENT METHOD AND COMPOSITION
TECHNICAL FIELD
This invention relates to an ectoparasitic treatment method and composition.
In particular, the present invention relates to the treatment of biting lice on sheep, although it
should be appreciated that aspects of the present invention can be extended to related matters.
BACKGROUND ART
Ectoparasites are a significant animal health concern as well as significantly affecting
production and increasing labour and capital costs.
In general, there are many ways to treat ectoparasites, but it is a continual battle to find new
and more effective treatments.
Referring now to a specific problem the inventors seek to address, lice and blowflies are the
two most significant external parasite problems experienced by sheep in Australia. Both
parasite groups cause extensive production losses and serious animal welfare concerns. Of
these two ectoparasite groups only the lice are obligate and permanent sheep parasites. That
is, they are dependent on spending their entire life cycle on sheep. The most prevalent and
most important of the sheep lice is the biting louse, Bovicola (formerly Damalinia) ovis.
Lice are typically categorised into those that feed directly on the blood of the host, i.e. sucking
lice, and those that feed on the skin surface (e.g. on secretions and skin debris), i.e. biting (or
chewing) lice. Three species of sucking louse are known to occur on sheep but are rarely
identified or implicated in production losses or disease in Australia. These are Linognathus
ovillus (the face louse) and Linognathus pedalis (the foot louse) and Linognathus africanus
(O’Callaghan et al., 1989).
In Australia, lice have been estimated to cost the wool industry more than $120 million per
year. Such costs include expenditure on treatment and control of infestations as well as
production losses. Significant reductions in fleece value (e.g. up to 30%), greasy fleece weight
and clean fleece weight have all been demonstrated in lice-infested flocks (Wilkinson et al.,
1982; Niven & Pritchard, 1985; Elliott et al., 1986; Cleland et al., 1989). Lice infestation has also
been shown to detrimentally affect the colour of the fleece, i.e. making it less bright and more
1 rd
http://www.wool.com/Grow_LiceBoss.htm Accessed on: 3 May 2012.
James & Wells ref: 133719/3
yellow (Kettle and Lukies, 1982), and can result in the downgrading of skins due to ‘cockle’
(Heath, 1995a).
The impacts on animal welfare and production due to sheep lice (i.e. B. ovis) are a
consequence of the irritation experienced by infested sheep. Primarily, the sheep show signs of
pruritus (itchiness) such as rubbing, biting and scratching and these behaviours damage the
integrity of the fleece (e.g. causing ‘pulled’ or cotted wool). In some sheep the pruritus can be
intense and the irritation can manifest as changes to the skin, including increased scurf and
thickening of the epidermis and overlying lipid layer (Britt et al. 1986; Heath et al. 1995b). There
is variation between individual sheep susceptibility to lice and this may be linked to an immune
response to infestation (James 1999; James et al. 2002).
B. ovis are recognised as feeding on “skin scurf, lipids, loose stratum corneum squames and
bacteria” (James, Moon & Brown, 1998). Although most lice (particularly adults) have been
observed in the fleece, away from the skin surface, they are quite mobile and are likely to feed
on substrates other than just the loose debris present at that location (Sinclair, Butler & Picton,
1989). The feeding behaviour of B. ovis at skin level appears to occur only on the surface of the
epidermis and does not bring it into direct contact with the internal tissues or blood of the host.
Observations have determined that B. ovis “does not ingest nucleated keratinocytes and
apparently does not penetrate deeper than the outer layers of the stratum corneum” (James,
Moon & Brown, 1998).
Lice are transmitted between sheep via direct contact. Lice control relies upon effective
chemical treatment of an entire flock and subsequent biosecurity measures to prevent re-
infestation (i.e. exclusion of lice-infested sheep). Due to the surface-feeding habits of B. ovis, all
successful chemical treatments previously used have involved topical delivery of the lousicidal
chemical. The methods used can be broadly categorised into high-volume application of diluted
chemical (i.e. in water) or low-volume delivery of concentrated chemical formulations.
High-volume application methods used in the past have included plunge dips, shower dips,
jetting races and hand jetting. These methods require prolonged wetting of the animal or high-
pressure jets to ensure adequate penetration or saturation of the fleece with the chemical
solution (Rothwell, 2005). Although they have often proven to be very reliable some
disadvantages of these methods of application include the capital expenditure on equipment,
additional labour required, exposure of operators to chemical (Anon., 2006), stress to animals,
secondary disease problems (e.g. transmission of infections), in-use maintenance of adequate
chemical concentrations (Levot, 1995) and the safe disposal of left-over chemical solution
(Levot, Lund & Black, 2004; Beynon, 2012).
Low-volume application methods have become very popular due to their convenience and
include pour-on and spray-on formulations. These products are generally ready-to-use and the
James & Wells ref: 133719/3
operator applies them to individual sheep using a manual or gas-powered applicator. There is
inevitably a high concentration of chemical at the sites of application but its subsequent
distribution through the fleece and over the skin is uneven. Persistent chemical residues from
some of these products have been identified as a potential environmental risk when the wool is
processed at scouring plants (Anon., 2006). Furthermore, the uneven distribution and
persistence of sub-lethal concentrations of chemicals in the fleece have been implicated in
accelerating the development of insecticide resistance within sheep lice populations (Johnson,
Boray & Dawson, 1992; Rothwell, 2005).
Insecticide resistance within sheep lice populations in Australia has become a significant
problem. Reports of synthetic pyrethroid (SP)-based lousicide failures became frequent in the
mid-1980s and resistance to the insect growth regulator (benzoylphenyl urea) pour-on products
emerged around 2003-2004 (Levot & Sales, 2008). Chemical groups to which sheep lice in
Australia are generally regarded as susceptible include the organophosphates (OPs),
macrocyclic lactones (MLs), neonicotinoids and spinosyns. However, the limited number of
different product formulations containing these chemicals restricts the ability of sheep
producers to choose between different methods of application.
It is evident that an ideal lousicide will:
1) Incorporate an active ingredient to which sheep lice are known to be susceptible
2) Deliver a high level of lousicidal efficacy
3) Be safe for administration to sheep
4) Rapidly deliver lethal insecticide concentrations to all areas of skin where the lice reside
) Be convenient for the operator to apply
6) Minimise operator exposure to the chemical
7) Ensure minimal chemical residues persist in the fleece
8) Not require disposal of used or excess chemical into the environment
It can therefore be seen why there is continued research to find effective ways to treat
ectoparasites – biting ones in particular. An ideal treatment would achieve a high insect
mortality rate (via even exposure of the parasites to lethal chemical concentrations), have no
detrimental effects on the host animal, be cost effective and not labour intensive, and it would
be safe for operators and the environment.
It is an object of the present invention to address the foregoing problems or at least to provide
the public with a useful choice.
All references, including any patents or patent applications cited in this specification are hereby
incorporated by reference. No admission is made that any reference constitutes prior art. The
discussion of the references states what their authors assert, and the applicants reserve the
James & Wells ref: 133719/3
right to challenge the accuracy and pertinency of the cited documents. It will be clearly
understood that, although a number of prior art publications are referred to herein, this
reference does not constitute an admission that any of these documents form part of the
common general knowledge in the art, in New Zealand or in any other country.
Throughout this specification, the word "comprise", or variations thereof such as "comprises" or
"comprising", will be understood to imply the inclusion of a stated element, integer or step, or
group of elements integers or steps, but not the exclusion of any other element, integer or step,
or group of elements, integers or steps.
Further aspects and advantages of the present invention will become apparent from the
ensuing description which is given by way of example only.
DISCLOSURE OF THE INVENTION
According to one aspect of the present invention there is provided a method of treating an
animal infested with biting lice
characterised by the step of
administering internally to the animal a pharmaceutically effective amount of neonicotinoid such
that the neonicotinoid is present systemically within the animal.
According to a further aspect of the present invention there is provided a composition for
internal administration to an animal including a neonicotinoid in the order of 2% to 80% w/v.
Preferably the composition is formulated so as to enable systemic absorption of the
neonicotinoid active following administration.
Preferably the neonicotinoid is in an amount suitable for the control of biting lice on an animal.
The required quantity of neonicotinoid has been found to be 40 mg/kg or less, by weight of the
animal.
Preferably the composition is formulated to provide a controlled release of the neonicotinoid. By
formulating the composition to control the release of the active into the animal, it has
surprisingly been found that the total amount of active required to control the lice on the animal
can be reduced. Methods for formulating a composition with controlled release of an active are
well known to those skilled in the art.
In one aspect of the preferred invention, the composition contains a controlled-release agent.
Such controlled release agents are well known to those skilled in the art.
James & Wells ref: 133719/3
In one aspect of the preferred invention, the composition is formulated such that when used,
the release provides a peak plasma concentration of greater than 0.5 mg/L of neonicotinoid
following administration.
In another aspect of the preferred invention, the composition is formulated such that when
used, the release is controlled to provide a plasma concentration of neonicotinoid of greater
than 0.5 mg/L of neonicotinoid after 24 hours following administration.
A particularly preferred neonicotinoid for use in the composition is thiacloprid.
According to yet another aspect of the present invention there is provided the use of a
neonicotinoid for the manufacture of a medicament for the control of lice on an animal.
Preferably the neonicotinoid used for the manufacture is thiacloprid.
According to yet another aspect of the present invention there is provided a dosage regime to
treat biting lice on an animal characterised by the step of administering a neonicotinoid
internally with a dosage of 40 milligrams per kilogram or less.
Throughout the specification, the use of the present invention will be described in relation to the
treatment of biting lice on sheep (Bovicola ovis). It should be appreciated however that the
principles in the present invention could apply to and be useful in other situations – for example
treating biting insects on other ruminant and camelid species. Many of the problems
associated with sheep are also present in, for example, goats (e.g. due to Bovicola caprae) and
alpacas (e.g. due to Bovicola brevis).
The medicament can be administered to the animal by a variety of means.
For example, in one embodiment the medicament may be administered orally, for example with
a drench gun such as that used for other medicaments.
Alternatively, an injectable liquid may be used and delivered via an injector – for example such
as that used to deliver antibiotics.
However other methods may be incorporated, for example solid dose forms (e.g. tablets,
pellets, boluses, implants) or other routes of administration/absorption (e.g. transcutaneous,
transmucosal).
A critical aspect of the invention however is that regardless of the mode of administration, the
neonicotinoid is present systemically within the animal.
To appreciate the inventiveness of this approach the following information is given by way of
background.
James & Wells ref: 133719/3
The first major chemical group that included systemic pesticides used for control of
ectoparasites on animals were the OPs. These systemically-active chemicals were absorbed by
the animal and carried, via the bloodstream, to the parasite (Khan, 1964; Pitman & Rostas,
1981). During the 1960s there was a significant focus on development of systemic
parasiticides for livestock with over 100 new compounds tested during this period (Khan, 1969).
The new, systemically-active compounds significantly influenced the evolution of
ectoparasiticide products for livestock and three major trends were identified by Drummond
(1985):
1) A reduction in the amount of material applied dermally (i.e. from spray or dip, to pour-on,
to spot-on)
2) Increasing use of oral or percutaneously-absorbed chemicals to control various
ectoparasites
3) The development of sustained-release devices to provide prolonged efficacy
During this period extensive research was conducted into the systemic OP chemicals for use in
livestock species. There was a universal shift from high-volume to low-volume dermal
application methods (e.g. from dip to pour-on formulations) and the introduction of alternative
routes of administration of systemic ectoparasiticides (i.e. oral or injectable). Despite these
developments to products for other livestock and/or parasite species, no such advances
occurred in the control of sheep lice. That is, until introduction of the (non-systemic) SP pour-
ons in the early 1980s.
Therefore, for two decades (i.e. from 1958 until registration of the SPs), Australian sheep
producers were reliant upon OP and arsenic-based dips for control of sheep lice (Levot, 2001).
Numerous OPs were available for use on sheep, the most popular including: diazinon,
chlorfenvinphos, coumaphos, fenthionethyl and carbophenothion (Levot 2001). These
chemicals were usually applied by plunge or shower dipping – a mode of application intended
to bring the chemical into contact with the parasite rather than via systemic absorption (Pitman
& Rostas, 1981). Unfortunately, during this period, “the incidence of properties with lice was 25-
%” and “many treatments were ineffective” (Levot, 2001). In addition, there was regulatory
pressure to quarantine those flocks affected (Levot, 2001).
Within this context there was certainly strong demand for new and effective sheep lousicide
products during the 1960s and 1970s in Australia. Unfortunately none of the developments in
OP control of biting lice on other livestock species, e.g. cattle, were successful in sheep. For
example, a fenthion-based product for sheep (Tiguvon® Sheep Dip) was available in Australia
from the late 1960s. The efficacy of fenthion as a systemic insecticide for use in cattle was
described in 1967 (Cox, Mullee & Allen, 1967). Despite the subsequent development of fenthion
into a highly-effective systemic spot-on for sucking and biting lice on cattle (Tiguvon® Spot-On
James & Wells ref: 133719/3
Cattle Lice Insecticide), released in the early 1970s, a low-volume fenthion-based product was
never successfully developed for control of sheep lice.
Coumaphos was another OP with established systemic activity in cattle (Cox, Mullee & Allen,
1967) that was used extensively for control of sheep lice in Australia from the 1960s. As for
fenthion, neither coumaphos nor any of the other OP chemicals with recognised systemic
activity in other species and/or against blood-feeding parasites of sheep were developed into
systemically-active products for sheep lice control.
The next major class of parasiticides to be developed with systemic activity were the MLs.
These chemicals have been used extensively for control of internal and external parasites of
sheep and cattle since abamectin was introduced in Australia in 1985 (Holdsworth, 2005). The
term ‘endectocide’ was coined to describe the MLs because they have been so successful for
control of both internal (endo-) and external (ecto-) parasites. Abamectin, ivermectin,
doramectin eprinomectin and moxidectin have all demonstrated activity against biting lice on
cattle, i.e. Bovicola bovis (Titchener et al, 1994; Clymer et al, 1998; Colwell, 2002; Holste,
1997; Lloyd et al, 2001; Lloyd et al, 1996). However, due to their skin-surface feeding habits, B.
bovis are more susceptible to the topical formulations of MLs applied on or near the sites of
infestation than those administered by injection (Logan et al, 1993; Cleale, 2004). Consistent
with this observation is the fact that “sucking lice are typically more susceptible to injectable
formulations of macrocyclic lactones than are chewing lice” (Cleale et al, 2004).
Although the purely systemic route of ML delivery to B. bovis is not ideal, injectable products
based on doramectin and moxidectin carry claims to “aid in the control” of this parasite in
Australia. Products based on all of the MLs (except eprinomectin) have been registered and
used extensively since the 1980s for control of internal parasites of sheep in Australia. Topical
formulations, i.e. an ivermectin jetting concentrate and an abamectin pour-on, have been used
for control of B. ovis on sheep. However, despite the experience with biting lice in cattle, none
of the MLs delivered via the systemic route have been registered for control of biting lice on
sheep. Likewise, a search of the published literature does not yield evidence of any of the MLs
providing control of these sheep lice when administered via the systemic route.
Doramectin has shown efficacy against biting lice when administered by injection to cattle.
Based on published literature (Barber et al, 2003), this formulation was selected as a good
candidate to provide sufficient systemic levels to control sheep lice following injection. Doses up
to 3-times that recommended for cattle were administered to sheep with natural infestations of
B. ovis. No efficacy against the lice populations was observed (data not published).
The consensus in published literature is that, despite their activity against other ectoparasites of
sheep, the MLs delivered via the systemic route do not provide effective control of the biting
James & Wells ref: 133719/3
louse, B. ovis (Coop et al, 2002; Bates, 2004). In reference to B. ovis, Bates (2012) states
clearly: “No ML injection is effective against chewing lice”.
The reasons for the differences observed in ML activity following systemic administration for
biting lice on cattle and sheep are unclear. Although related, B. bovis and B. ovis are distinct
species of biting lice, which are known to be very host-specific. This means that each louse
species is highly adapted to its particular host animal species. In other words, B. bovis cannot
infest sheep and B. ovis cannot infest cattle. Given that the lice are host-adapted, there may be
differences in their biology (e.g. preferred skin substrates to feed on, frequency of feeding,
proximity to skin surface, mobility) that make B. bovis on cattle more susceptible to MLs (and
perhaps OPs) delivered via the systemic route.
Theoretically, chemicals present in the blood stream may be delivered to the skin surface by
diffusion between cells of the skin (intercellular), diffusion through cells of the skin
(intracellular), diffusion into the hair follicles, secretion in sweat, secretion in sebum or by
accumulation inside epidermal cells which gradually move towards the skin surface (Patzelt et
al 2008). It is not known precisely which of these mechanisms are responsible for the delivery
of ML and OP chemicals to the skin surface of cattle where they can exert an effect on B. bovis.
However, marked differences in the skin layers and appendages (i.e. hair follicles, sebaceous
glands and sweat glands) are known to occur between different species. For example, cattle
skin may have around 890 follicles/cm whereas a Merino sheep can have up to 10,000
follicles/cm (Mills & Cross, 2006). The density of blood vessels, thickness of the skin, and the
rate and composition of the sebaceous secretions can also differ (Mills & Cross, 2006). It is
evident that the significant structural and physiological differences between the skin of cattle
and sheep could certainly influence the delivery of chemicals to biting lice feeding on the skin
surface.
In preferred embodiments, thiacloprid is the neonicotinoid used. While neonicotinoids are
known as a class of insecticides, the inventors have determined that not all of these have
similar potency to thiacloprid when used against biting lice in sheep via the systemic route. For
example, imidacloprid is one such related compound.
It is thought however that other members of the neonicotinoid insecticide class may also have
the physicochemical properties, similar to thiacloprid, that are required to be effective via this
route.
It is believed by the inventor that contrary to expectations, a systemic introduction of a
neonicotinoid causes the chemical to be present in vectors that biting lice feed on, for example
skin, skin secretions and associated debris (e.g. dead cells) at concentrations sufficient to be
lousicidal.
James & Wells ref: 133719/3
It should be appreciated that the present invention can be co-formulated with other active
ingredients, for example anthelmintic treatments, vaccines, vitamins/mineral supplements and
the like. Not only does this offer advantages by having two or more treatments being delivered
in a single dose, but there may also be complementary effects resulting. For example, the
inclusion of vitamins and minerals may assist the skin recovery of an animal once the biting lice
have disappeared as a result of the insecticide treatment.
As mentioned previously, the thiacloprid can be administered in a dosage of 40 milligrams per
kilogram or less. It should be appreciated that considerable care is required when developing
systemic treatments as a greater dose can lead to toxicity and harm to the animal, while too
small a dose can lead to ineffectiveness.
As can be seen in the trial data discussed in the Best Modes portion of the specification, a
single dose of 40 milligrams per kilogram of animal has been found to be very effective.
However, for reasons of safety and cost effectiveness, smaller dosages are preferred.
Dosages of thiacloprid at 20 milligrams per kilogram in a single dose has been found to be
effective by the inventors in clearing over 99% of lice (Bovicola ovis) after 69 days.
Likewise, split dosing of 15 milligrams per kilogram on day 0 and 15 milligrams per kilogram on
day 1 were equally effective.
For optimum safety thresholds, a dosage of around 5 milligrams per kilogram would be
desirable – yet a single dosage of 4 milligrams per kilogram was only partially effective in
clearing lice.
Surprisingly, the inventors have found that a split dosage of 1 milligrams per kilogram on two
consecutive days was significantly better than the 4 milligrams per kilogram on 1 day.
Therefore it appears that the present invention would be more effective if the neonicotinoid is
administered over a period of time. This could include the administration of a number of
discrete dosages over a few days, or alternate embodiments could involve the use of a slow
release device.
Naturally, the composition being administered will vary dependent upon the administration route
and whether a single dose will be used or the active is to be administered over time. Further,
as discussed previously, the present invention can be used with other actives as well.
Nevertheless, it is envisaged that preferred compositions will include neonicotinoid in the order
of 2% to 80% w/v. As can be seen in the examples given, a formulation having the
neonicotinoid in the order of 40% is particularly stable.
James & Wells ref: 133719/3
In preferred formulations, in addition to the active there may be provided dispersing agents,
preservatives, anti-foaming agents and humectants. Thiacloprid is water soluble and therefore
it is envisaged that water would be a carrier in preferred embodiments of the present invention.
It can be seen that the present invention has a number of advantages over the prior art.
Firstly, there is provided an alternate treatment for biting lice which does not have the intensive
labour requirement, capital overheads and potential human health risks of topical treatments.
Further, by determining a systemic administration route, and an appropriate dosage level then
equal delivery of a sufficiently high dosage to all of the parasites can be ensured – providing
reliable efficacy and avoiding factors that accelerate the development of insecticide resistance.
Further, minimization of insecticide residues in the fleece will reduce the risks to the
environment secondary to wool processing.
BRIEF DESCRIPTION OF THE DRAWINGS
Further aspects of the present invention will become apparent from the ensuing description
which is given by way of example only and with reference to the accompanying drawings in
which:
Figure 1 Illustrates mean plasma thiacloprid concentrations in accordance with treatment
regimes in accordance with the present invention.
Figure 2 Further illustrates mean plasma thiacloprid concentrations in accordance with
treatment regimes in accordance with the present invention.
BEST MODES FOR CARRYING OUT THE INVENTION
Below are shown formulations which have worked in accordance with one embodiment of the
present invention.
T1844 %w/v
Thiacloprid (Micronised) ** 5.00
Xanthan gum 0.2
Polysorbate 80 2.5
Methyl paraben 0.2
James & Wells ref: 133719/3
Propyl paraben 0.04
Plasdone K25 3
wacker silica 1
citric acid 1.75
Sodium hydroxide 0.95
Defoamer RD 0.1
Deionised water qs
T1836 %w/v
Thiacloprid (Micronised) ** 7.875
Cremophor EL 2.0
N-Methyl - 2 –Pyrroidone (NMP) 40.0
Glycerine formal stabilised q.s.
T1837 %w/v
Thiacloprid (Micronised) ** 10.5
Benzyl alcohol 1.0
Span 80 (sorbitan monooleate) 0.10
Phospholipon H90 (Phosphatidylcholine , hydrogenated) 0.10
Cotton seed oil q.s.
** 5% overages added.
It should be appreciated that these figures are given by way of example only, and that other
formulations can be used in accordance with the present invention.
The resultant plasma concentration of thiacloprid following administration of the above three
formulations is shown in Figure 1.
Below are results of a trial which utilised the above formulations and provides support for the
present invention
Table 1 Sheep Lice Count Reductions (%)
Formulation Route of Dose Days after treatment
Admin. (mg/kg)
7 14 28
James & Wells ref: 133719/3
T1844 Oral 5 93.6% 86.6% 51.1%
T1836 Subcutaneous 5 80.4% 84.9% 20.6%
injection
T1837 Subcutaneous 5 96.4% 76.9% 5.8%
injection
Below are results of trials which utilised an earlier formulation (that included thiacloprid as the
active ingredient) and provide further support for the present invention.
Table 2 Sheep Lice Count Reductions (%)
Route of Weeks after Treatment
Dose
Admin.
(mg/kg)
2 3 4 6 10 15
Oral 50 100 100 100
Oral 48 100 98.3 93.0
Oral 40 99.7 99.7 100
Oral 30 99.7 100 99.7
Oral 15+15* 100 100 100
Oral 20 100 99.0 99.4
Oral 4 63.1 50.9 31.9
Oral 1+1* 84.4 70.3 71.4
Oral 0.5 46.5 5.6 0
* Doses split over 24 hours (e.g. 15 mg/kg on Day 0 then 15 mg/kg on Day 1)
Additional formulations to be delivered orally and/or via injection are given below. In particular it
should be noted that castor oil has been chosen for this purpose, as it is known to provide a
prolonged release of lipophilic actives.
Thiacloprid Oral 5%
T1919 T1920 T1921
Ingredients %w/v %w/v %w/v
Thiacloprid 5.0* 5.0** 5.0**
Xanthan gum 0.2 0.2 0.2
Polysorbate 80 2.5 12 20
Methyl paraben 0.2 0.2 0.2
Propyl paraben 0.04 0.04 0.04
Plasdone K25 3 3 3
Wacker silica 1 1 1
Citric acid 1.75 1.75 1.75
Sodium hydroxide 0.95 0.95 0.95
James & Wells ref: 133719/3
Castor oil 0 3 5
Defoamer RD 0.1 0.1 0.1
Deionised water qs qs qs
*Non micronized active
**Micronized active
Thiacloprid Injection 10%
T1909 T1910 T1911
Ingredients %w/w %w/w %w/w
Thiacloprid 10.0 * 10.0** 10.0**
Benzyl alcohol 1.00 1.00 1.00
Span 80 (Sorbiton Monooleate) 0.10 0.10 0.10
Phospholipon H90 (Phosphatidylcholine ,
0.1 0.1 0.1
hydrogenated
Castor oil 0 5 10
Cotton Seed oil QS QS QS
The above oral and injectable formulations were tested for efficacy against Bovicola ovis in
sheep, at a dose rate of ~ 5 mg/kg. Each group in the trial consisted of 4 sheep, and doses
were determined for each individual sheep based on weight. The injectable formulations were
administered subcutaneously, and the oral formulations were administered by syringe directly
into the mouth. No adverse events occurred during the trial and all treatments appeared to be
well tolerated. The results are shown in Table 3. The profiles of the plasma concentrations
illustrate the effects of the different aspects of the formulations that control the release of the
active. In these examples such factors include particle size of the active, surfactant
concentration and the release-controlling agent castor oil.
James & Wells ref: 133719/3
Table 3 Sheep Lice Count and Efficacy (%)
Geometric Mean of Lice Count Treatment Efficacy
Group Treatment Day -5 Day 14 Day 29 Day 57 Day 14 Day 29 Day 57
1 T1909 191.16 289.53 213.77 146.65 --- --- 23%
(10% injection)
2 T1910 225.28 121.00 84.37 91.63 46% 63% 59%
(10% injection)
3 T1911 235.22 180.91 162.78 62.57 23% 31% 73%
(10% injection)
4 T1919 191.80 93.52 41.54 27.64 51% 78% 86%
(5% oral)
T1920 252.37 163.31 42.13 71.43 35% 83% 72%
(5% oral)
6 T1921 222.17 38.62 33.76 35.33 83% 85% 84%
(5% oral)
The resultant plasma concentration of thiacloprid following administration of the above six
formulations is shown in Figure 2.
As can be seen from these results, there are significant differences in efficacy levels many
weeks following administration that are dependent on the initial release/absorption
characteristics of the formulations. The results demonstrate the additional advantage of
controlling the release of the active to maintain an initial minimum plasma concentration of
active over time.
Aspects of the present invention have been described by way of example only and it should be
appreciated that modifications and additions may be made thereto without departing from the
scope thereof as defined in the appended claims.
Claims (17)
1. A method of treating a sheep infested with Bovicola ovis characterized by the step of administering internally to the animal a pharmaceutically effective amount of neonicotinoid such that the neonicotinoid is present systemically within the animal.
2. A method as claimed in claim 1 wherein the administration route is oral.
3. A method as claimed in claim 1 wherein the administration route is via injection.
4. A method as claimed in any one of claims 1 to 3 wherein the neonicotinoid is thiacloprid.
5. A method as claimed in any one of claims 1 to 4 wherein the thiacloprid is administered in a dosage of 40 milligrams per kilogram or less of the animal.
6. A method as claimed in any one of claims 1 to 5 wherein the neonicotinoid is administered over a period of time.
7. A method as claimed in claim 6 wherein the neonicotinoid is administered in multiple doses.
8. A method as claimed in claim 6 wherein the neonicotinoid is administered in slow release form.
9. An applicator designed for internal administration to a sheep, containing a composition including a neonicotinoid in the order of 2% to 80% w/v.
10. A dosage regime to treat Bovicola ovis on a sheep characterised by the step of administering a neonicotinoid internally with a dosage in the order of 40 milligrams per kilogram or less of the animal.
11. A dosage regime as claimed in claim 10 wherein the administration is over a period of time.
12. A dosage regime as claimed in claim 10 wherein the neonicotinoid is administered in multiple doses.
13. A dosage regime as claimed in claim 11 wherein the neonicotinoid is administered by a slow release route.
14. A dosage regime as claimed in the previous claim wherein the neonicotinoid is administered to the animal in the order of two or more 1 milligram per kilogram dosages spaced apart by a day or more.
15. A method as claimed in claim 1 substantially as herein described in the Best Modes Section with reference to and as illustrated by the accompanying formulations T1844, T1863, T1837, Thiacloprid Oral 5% and Thiacloprid Injection10%.
16. A composition for use in the treatment of Bovicola ovis on a sheep substantially as herein described in the Best Modes Section with reference to and as illustrated by the accompanying formulations T1844, T1863, T1837, Thiacloprid Oral 5% and Thiacloprid Injection 10%.
17. A dosage regime as claimed in claim 10 for sheep substantially as herein described in the Best Modes Section with reference to and as illustrated by the accompanying formulations T1844, T1863, T1837, Thiacloprid Oral 5% and Thiacloprid Injection 10%.
Publications (1)
Publication Number | Publication Date |
---|---|
NZ613078B2 true NZ613078B2 (en) | 2016-05-11 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2473760C (en) | Topical ivermectin composition | |
JP2023154054A (en) | Antiparasitic pour-on compositions | |
AU2013204134B2 (en) | Ectoparasitic Treatment Method and Composition | |
Sulik et al. | Antiparasitic activity of ivermectin: Four decades of research into a “wonder drug” | |
AU2016202546A1 (en) | Ectoparasitic treatment method and composition | |
JP4677405B2 (en) | Anthelmintic composition | |
CN107157995B (en) | A kind of compound imidacloprid transdermal composition preparation of pet broad-spectrum anti-parasite | |
NZ613078B2 (en) | Ectoparasitic Treatment Method and Composition | |
AU2018372008B2 (en) | Composition containing moxidectin for treating parasites infestations | |
NZ617203B2 (en) | Ectoparasitic treatment method and composition | |
NZ617203A (en) | Ectoparasitic treatment method and composition | |
CA2885964C (en) | Ectoparasiticidal methods and formulations comprising spinetoram, benzyl alcohol and propylene carbonate | |
AU2014280848B2 (en) | Ectoparasitic treatment method and composition | |
CN115317498B (en) | Compound drop for treating canine and feline parasites and fungal skin diseases and preparation method thereof | |
AU2017200250B2 (en) | A Tick Treatment | |
NZ754349A (en) | Ectoparasitic treatment method and composition | |
NZ754349B2 (en) | Ectoparasitic Treatment Method and Composition | |
AU2003236560A1 (en) | Worming formulation |